Wayne State University

AIM HIGHER

Technology Commercialization

A Single Nucleotide Polymorphism Predicts Human Cancer Risk Associated with Racial Disparity

<- Return to Search Page

Categories
Biotechnology, Diagnostics
Summary
This invention is a new diagnostic tool which allows prediction of cancer risk based on a single nucleotide polymorphism of a gene whose protein is over-expressed in various cancers. The polymorphism results in a single amino acid change. DNA analysis demonstrated that 98% of cancer patients tested had the mutation while normal donors did not. The extreme high frequency of the mutation suggests that it can be used to custom tailor the frequency of screening tests such as mammograms depending on whether or not an individual carries the mutation. Analysis of this mutation may also provide information to clinicians in evaluating the risk of tumor transition from benign to malignant,potentially affecting the decision to perform surgical procedures. Detection of the mutation can be carried out using routine clinical laboratory methods.
File number
07-866
Data
Data is available upon completion of a confidentiality agreement.
Publications
A patent application is on file.
Contact
Randy Ramharack Technology Licensing Manager Phone: 313-577-5541 Fax : 313-577-2814 randy.ramharack@wayne.edu